[1] Yang X, Sun D, Xiang H, et al. Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD. Hepatology,2021,74:1319-1338.
[2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64:73-84.
[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73:202-209.
[4] Poisson J, Lemoinne S, Boulanger C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol,2017,66:212-227.
[5] Dixon LJ, Barnes M, Tang H, et al. Kupffer cells in the liver. Compr Physiol,2013,3:785-797.
[6] Marrone G, Shah VH, Gracia-Sancho J Sinusoidal communication in liver fibrosis and regeneration. J Hepatol,2016,65:608-617.
[7] Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology,2011,54:344-553.
[8] Ma N, Wang YK, Xu S, et al. PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. Nat Commun,2021,12:3059.
[9] Chalasani N, Wilson L, Kleiner DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol,2008,48:829-834.
[10] Cataldo I, Sarcognato S, Sacchi D, et al. Pathology of non-alcoholic fatty liver disease. Pathologica,2021,113:194-202.
[11] Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest,2005,115:1343-1351.
[12] Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci,2018,75:3313-3327.
[13] Rada P, González-Rodríguez Á, García-Monzón C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis,2020,11:802.
[14] Nguyen TTP, Kim DY, Lee YG, et al. SREBP-1c impairs ULK1 sulfhydration-mediated autophagic flux to promote hepatic steatosis in high-fat-diet-fed mice. Mol Cell,2021,81:1-13.
[15] Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology,2008,134:424-431.
[16] 邵幼林, 范建高. 非酒精性脂肪性肝病患者肝脏脂肪的来源与去路. 国际消化病杂志,2019,39:316-320.
[17] Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology,2007,46:1081-1090.
[18] Zhang MH, Li J, Zhu XY, et al. Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress. Free Radic Biol Med,2021,164:1-12.
[19] Chen L, Wu N, Kennedy L, et al. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. Hepatology,2021,74:1845-1863.
[20] Afonso MB, Rodrigues PM, Mateus-Pinheiro M, et al. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut,2021,70(12):2359-2372.
[21] Tosello-Trampont AC, Landes SG, Nguyen V, et al. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem,2012,287:40161-40172.
[22] Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 ((MCP-1)) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut,2012,61:416-426.
[23] Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol,2017,66:1037-1046.
[24] Kremer M, Hines IN, Milton RJ, et al. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology,2006,44:216-227.
[25] Ghazarian M, Revelo XS, Nøhr MK, et al. Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome. Sci Immunol,2017,2((10)):eaai7616.
[26] Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med,2011,17:610-617.
[27] Lackner C, Gogg-Kamerer M, Zatloukal K, et al. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol,2008,48:821-828.
[28] Guy CD, Suzuki A, Burchette JL, et al. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol,2012,43:790-800.
[29] Schwabe RF, Tabas I, Pajvani UB Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology,2020,158:1913-1928.
[30] Chen L, Wu N, Kennedy L, et al. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. Hepatology,2021,74:1845-1863.
[31] Torbenson M, Chen YY, Brunt E, et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol,2006,30:508-513.
[32] Tandra S, Yeh MM, Brunt EM, et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol,2011,55:654-659.
[33] Jia M, Zhang H, Qin Q, et al. Ferroptosis as a new therapeutic opportunity for nonviral liver disease. Eur J Pharmacol,2021,908:174319.
[34] Li X, Wang TX, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient ((MCD))-diet induced NASH by suppressing liver lipotoxicity. Liver Int,2020,40:1378-1394.
[35] Britton L, Jaskowski LA, Bridle K, et al. Ferroportin Expression in Adipocytes Does Not Contribute to Iron Homeostasis or Metabolic Responses to a High Calorie Diet. Cell Mol Gastroenterol Hepatol,2018,5:319-331. |
